Urogen Pharma Ltd.

This study tests a drug called UGN-102 for people with a low-grade, intermediate-risk type of bladder cancer that hasn't spread into the muscle. The goal is to see if this drug can destroy the cancer without needing surgery. About 240 participants received the drug, and researche…

This study tests a new drug called UGN-103, which is placed directly into the bladder, to treat a type of low-grade bladder cancer that hasn't spread into the muscle. About 99 people with this cancer at intermediate risk of coming back will receive the treatment. The main goal is…